CVS Health will raise its quarterly shareholder payout by 27 percent, and the nation's second-largest drugstore chain also said Tuesday that it expects another year of earnings growth in 2015.. CVS Health drew national attention earlier this year when it announced a plan to stop selling tobacco products in its stores as it sharpens its focus on delivering...» Read More
After a difficult January, when shoppers first felt the effect of a payroll tax hike that lowered take-home pay by 2 percent, some retailers got a little relief in February from growing employment and a rising stock market.
Containing health care costs, promoting innovation and the treatment of deadly diseases are among the biggest challenges the U.S. faces, Johnson and Johnson CEO Alex Gorsky said on Thursday.
Moves by Indonesia's President Susilo Bambang Yudhoyono to put his finance minister in charge of the central bank is leading to concerns that he may be seeking someone more malleable to run the state coffers in the run up to next year's elections.
The pharmaceutical and biopharmaceutical sectors have been marching steadily higher. TheStreet.com reports on two stocks with potential to appreciate.
Mylan's aquisition of Agila is expected to double its business. Heather Bresch, Myland CEO, offers insight.
CNBC's Brian Shactman reports the Department of Justice is joining Floyd Landis in a lawsuit accusing Lance Armstrong using performance-enhancing drugs while being sponsored by the U.S. Postal Service. Armstrong says he did not cost the government money. Instead, he says the Postal Service actually benefitted to the tune of more than $100 million from its association with the disgraced cyclist.
Turberculosis is making a global comeback, including in the United States. Dr. William Schaffner of Vanderbilt University School of Medicine, discusses the concern surrounding the disease.
Retail sales barely rose in January as tax increases and higher gasoline prices restrained spending. Separately, import and export prices rose slightly less than expected in the month.
Washington State's liquor control board is seeking a marijuana consultant to help forge ahead regulation for its newly legalized substance. Steve Fox, director of government relations with the Marijuana Policy Project, offers insight.
Opko Health chairman and CEO Dr. Phillip Frost, offers insight on his company's acquisition of Cytochromas, its partnerships with companies like Bristol-Meyers Squibb, and where the company is headed this year.
Watson Pharmaceuticals has merged with Actavis, and will now trade on the NYSE under ticker symbol ACT. Its president & CEO Paul Bisaro, discusses the U.S. economy and the generic drug industry.
The world is gearing up for Lance Armstrong's big interview tonight with Oprah Winfrey. Robbie Vorhaus, founder & CEO of Vorhaus Communications, weighs in.
The relative prospects for shares of Pfizer and Johnson & Johnson are debated by a fundamental analyst and a technical analyst. (2:58)
In the wake of Johnson & Johnson's manufacturing problems, CVS has changed the way it stocks Tylenol, reports CNBC's Bertha Coombs.
NBC's Anne Thompson reports Lance Armstrong confessed to using performance enhancing drugs in an interview with Oprah Winfrey; and CNBC's Scott Cohn reports Armstrong has now complied with the subpoena for all of his medical records.
Could a widely used MS treatment work on other diseases?
The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.
Retailers should be buzzing right now with holiday gift card redemptions. But, there's early evidence retailers aren't getting much of a boost from gift cards this year, according to NBG Market Analyst Brian Sozzi.
Onyx Pharmaceuticals CEO Dr. Anthony Coles discusses his company's thyroid cancer drug and its blood cancer drug and its partnership with Bayer.
NPS Pharmaceuticals CEO Dr. Francois Nader discusses the approval of its short bowel syndrome drug Gattex, and what's next for the company.